Intermediate dose 5-fluorouracil-induced encephalopathy

Japanese Journal of Clinical Oncology

Volumn 36, Issue 1, 2006, Pages 55-59

  Kim, Yeon A ^a   Chung, Hyun Cheol ^a   Choi, Hye Jin ^a   Rha, Sun Young ^a   Seong, Jin Sil ^a   Jeung, Hei Cheul ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Anal cancer; Encephalopathy; Hyperammonemia

Indexed keywords

AMMONIA; CISPLATIN; DEXAMETHASONE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; ONDANSETRON;

AGED; AMMONIA BLOOD LEVEL; ANUS CANCER; ARTICLE; BRAIN TOXICITY; CASE REPORT; COGNITIVE DEFECT; CONFUSION; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; DISORIENTATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; HUMAN; HYPERAMMONEMIA; LABORATORY DIAGNOSIS; MALE; MEMORY DISORDER; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEUROTOXICITY; REAL TIME POLYMERASE CHAIN REACTION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CISPLATIN; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; HUMANS; HYPERAMMONEMIA; INFUSIONS, INTRAVENOUS; MALE; NEOPLASM INVASIVENESS; NEUROTOXICITY SYNDROMES;

EID: 32244443581     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hyi214     Document Type: Article

References (18)

1. Pirzada NA, Ali II, Dafer RM. Fluorouracil-induced neurotoxicity. Ann Pharmacother 2000;34:35-8.
2. Langer CJ, Hageboutros A, Kloth DD, Roby D, Shaer AH. Acute encephalopathy attributed to 5-FU. Pharmacotherapy 1996;16:311-3.
3. Cossaart N, SantaCruz KS, Preston D, Johnson P, Skikne BS. Fatal Chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer. Bone Marrow Transplant 2003;31:57-60.
4. Price RA, Jamieson PA. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 1975;35:306-18.
5. Moertel CG, Reitemeier RJ, Bolton CF, Shorter RG. Cerebellar ataxia associated with fluorinated pyrimidine therapy. Cancer Chemother Rep 1964;41:15-8.
6. Riehl J, Brown WJ. Acute cerebellar syndrome secondary to 5-fluorouracil therapy. Neurology 1964;14:961-7.
7. Kemeny N, Younes A, Seiter K, Kelsen D, Sammarco P, Adams L. Interferon alpha 2a and 5-fluorouracil for advanced colorectal carcinoma. Cancer 1990;66:2470-5.
8. Yeh KH, Cheng AL. High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 1997;75:464-5.
9. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, et al. Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 1994;12:2248-53.
10. Takimoto CH, Lu ZH, Zhang R, Liang MD. Larson LV, Cantilena LR Jr, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 1996;2:477-81.
11. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993;53:5433-8.
12. Lazar A, Mau-Holzmann UA, Kolb H, Reichenmiller HE, Riess O, Schomig E. Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Onkologie 2004;27:559-62.
13. Koenig H, Patel A. Biochemocal basis for fluorouracil neurotoxicity. Arch Neurol 1970;23:166-60.
14. Okeda R, Karakama T, Kimura S, Toizumi S, Mitsushima T, Yokoyama Y. Neuropathologic study on chronic neurotoxicity of 5-fluorouracil and its masked compounds in dogs. Acta Neuropathol 1984;63:334-43.
15. Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Bochem 2000; 278:175-84.
16. Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, et al. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: Possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000;91:105-12.
17. Sakurai Y, Uraguchi T, Imazu H, Hasegawa S, Matsubara T, Ochiai M, et al. Changes in thymidylate synthase and its inhibition rate and changes in Dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenografts SC-1-NU. Gastric Cancer 2004;7:110-6.
18. Liaw CC, Wang HM, Wang CH, Yang TS, Chen JS, Chang HK, et al. Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-FU with the complication of dehydration and infection. Anticancer Drugs 1999; 10:275-81.